Finberg J P, Youdim M B
Br J Pharmacol. 1985 Jun;85(2):541-6. doi: 10.1111/j.1476-5381.1985.tb08891.x.
The selective monoamine oxidase (MAO) inhibitors clorgyline, selegiline and AGN 1135 did not cause a change in responses of the cat nictitating membrane to preganglionic sympathetic nerve stimulation at 5 Hz. Both selective MAO-A and MAO-B inhibitors markedly potentiated nictitating membrane contractions in response to beta-phenylethylamine (PEA). However, the responses to tyramine were unchanged. The pressor responses to tyramine were potentiated by the selective MAO-A inhibitor clorgyline (2 mg kg-1) but not by selegiline (1.0 mg kg-1) and AGN 1135 (1.5 mg kg-1), selective MAO-B inhibitors. At the doses used selegiline and AGN 1135 caused a near total selective inhibition of liver and brain MAO-B, while clorgyline inhibited MAO-A only in the brain. AGN 1135, like selegiline, could be a useful drug in potentiating the action of L-DOPA in Parkinson's disease.
选择性单胺氧化酶(MAO)抑制剂氯吉兰、司来吉兰和AGN 1135不会改变猫瞬膜对5Hz节前交感神经刺激的反应。选择性MAO - A和MAO - B抑制剂均能显著增强瞬膜对β - 苯乙胺(PEA)的收缩反应。然而,对酪胺的反应未发生变化。选择性MAO - A抑制剂氯吉兰(2mg/kg)能增强对酪胺的升压反应,但选择性MAO - B抑制剂司来吉兰(1.0mg/kg)和AGN 1135(1.5mg/kg)则不能。在所使用的剂量下,司来吉兰和AGN 1135几乎完全选择性抑制肝脏和脑内的MAO - B,而氯吉兰仅抑制脑内的MAO - A。与司来吉兰一样,AGN 1135可能是一种增强左旋多巴在帕金森病中作用的有用药物。